Diamyd Medical AB
Company Profile
Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWET: +46 86610026
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2027
Employees
45
Stocks News & Analysis
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
stocks
Investor Playbook: Can your portfolio handle what’s next?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.40 | 39.10 | -0.42% |
| CAC 40 | 8,352.00 | 16.91 | -0.20% |
| DAX 40 | 26,598.64 | 151.31 | -0.57% |
| Dow JONES (US) | 51,880.64 | 466.91 | -0.89% |
| FTSE 100 | 10,881.55 | 21.01 | -0.19% |
| HKSE | 23,753.84 | 116.24 | 0.49% |
| NASDAQ | 24,628.23 | 508.04 | -2.02% |
| Nikkei 225 | 59,662.02 | 1,480.33 | -2.42% |
| NZX 50 Index | 14,303.77 | 130.09 | 0.92% |
| S&P 500 | 7,452.26 | 109.41 | -1.45% |
| S&P/ASX 200 | 9,044.70 | 37.50 | -0.41% |
| SSE Composite Index | 3,602.57 | 31.78 | -0.87% |